US President Donald Trump announced a fresh round of tariffs, including a 100% duty on branded or patented pharmaceuticals ...

AstraZeneca and Daiichi's Enhertu wins FDA priority review in breast cancer, backed by phase III data showing a 44% lower ...

AstraZeneca and Daiichi Sankyo have announced that their supplemental Biologics License Application (sBLA) for Enhertu ...

Researchers examined invasive disease-free survival rates at 4 years in a randomized phase 3 trial of adjuvant treatment for ...

The Institute of Cancer Research, London, has uncovered a promising new treatment target for pancreatic cancer, identifying the protein SPP1 as a ...

The pharmaceutical sector has seen a flurry of new deals, partnerships, and drug launches this week, presenting potential ...

Patients receiving ribociclib 400 mg had a shorter QTcF (12.5 vs 19.7 ms at cycle 1 day 15, 2 hours post-dose) and a lower rate of grade 3 or 4 neutropenia (41% vs 58.5%); they were also less likely ...

Enhertu plus pertuzumab granted Priority Review in US as 1st-line treatment for patients with HER2-positive metastatic breast cancer: Cambridge, UK Thursday, September 25, 2025, 0 ...

The deal involves an upfront payment of $18 million, followed by regulatory and commercial milestone payments of up to $1.093 ...

Trastuzumab deruxtecan is a HER2-directed antibody and topoisomerase inhibitor conjugate currently marketed under the brand name Enhertu as a second-line therapy for HER2-positive metastatic breast ...

The FDA granted priority review for trastuzumab deruxtecan in combination with pertuzumab for first-line treatment of adults ...

Patients on Enhertu and Perjeta lived more than three years without disease progression compared to just over two years on Perjeta, Herceptin, and chemo.